The North American ambulatory infusion pumps market is projected to generate $1,989.8 million revenue by 2030, advancing at a CAGR of 8.5% during 2021–2030. The key factors driving the market include the surging prevalence of chronic diseases, rising geriatric population, increasing diabetic population, and growing demand for ambulatory services.
The pandemic has caused an unexpected boom in the pharmaceutical industry, due to the shift in the focus toward healthcare. This has positively impacted the market for ambulatory infusion pumps. Hence, despite the lockdowns and factory closures implemented by governments, several pharmaceutical and medical device manufacturers continued their normal operations. For instance, Becton, Dickinson and Company revealed that all its manufacturing and distribution centers were operational during the COVID-19 pandemic.
Moreover, post-lockdown, pharmaceutical and medical device companies have resumed their operations with the full workforce, to manufacture drug delivery devices and infusion pumps at a higher pace. Additionally, the COVID-19 pandemic has increased the demand for home-use delivery devices. The reason behind this is the implementation of lockdowns and the growing preference of people to stay home, in order to reduce the chances of catching the infection. Thus, those earlier visiting a hospital or clinic for their drug dose are now preferring to stay indoors and opting for ambulatory infusion pumps.
The intravenous category held the largest share, around 75%, in 2021. Medications, hormones, chemotherapy agents, painkillers, and nutritious fluids are administered into the circulatory system through the veins in controlled volumes, using intravenous infusion pumps. These pumps are widely used in hospitals, nursing homes, and homes. Using built-in software, a skilled operator controls the pump, by setting the rate and duration of the fluid supply.
Moreover, the direct category held the larger share in 2021. This is mainly because direct distribution allows businesses to cut out the high markups and expenses related to using middlemen to distribute their goods. Companies that sell directly to their customers enjoy higher profit margins on their products.
Moreover, the U.S. held the larger share in the North American ambulatory infusion pumps market, owing to the increasing geriatric population in the country. More than 1.4 million adults in the U.S. live in nursing homes, including about 15.5% of the people younger than 65 years and approximately 41.6% of the people over 85 years. The incidence of chronic pain amongst elderly people in nursing homes is very high, and pain in this age group is a serious problem for care facilities.
The major players operating in the North American ambulatory infusion pumps market include B. Braun Melsungen AG, Moog Inc., WalKMed LLC, Medtronic plc, Fresenius Medical Care AG & Co. KGaA (Fresenius Kabi), Becton, Dickinson and Company, Repro Med Systems Inc. (KORU Medical Systems), Avanos Medical Inc., ICU Medical Inc., Eitan Medical, and Ace Medical Co. Ltd.